{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.0"},{"groupId":"OG001","value":"29.3"}]}],"title":"Taking any analgesic medication"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9"},{"groupId":"OG001","value":"1.7"}]}],"title":"Discontinued at least 1 medication"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3"},{"groupId":"OG001","value":"0.3"}]}],"title":"Decreased dose of at least 1 medication"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5"},{"groupId":"OG001","value":"7.1"}]}],"title":"No change in any medication"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.2"},{"groupId":"OG001","value":"20.1"}]}],"title":"Increased dose or added at least 1 medication"}],"denoms":[{"counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"294"}],"units":"Participants"}],"description":"Analgesic medications were recorded throughout the study until disease progression.","groups":[{"description":"Participants received fluoropyrimidine (EITHER 5-FU or capecitabine, at the investigator's discretion) and cisplatin once every 3 weeks (one cycle) for a maximum of 6 cycles as follows: cisplatin 80 mg/m\\^2, IV, on Day 1 and EITHER: 5-FU 800 mg/m\\^2 continuous IV infusion on Days 1 through 5 OR capecitabine 1000 mg/m\\^2, tablets, PO, BID from the evening of Day 1 through the morning of Day 15.","id":"OG000","title":"Fluoropyrimidine/Cisplatin (FP)"},{"description":"Participants received trastuzumab plus fluoropyrimidine (EITHER 5-FU or capecitabine, at the investigator's discretion) and cisplatin once every 3 weeks (one cycle) for a maximum of 6 cycles (except as noted) as follows: trastuzumab 8 mg/kg, IV, on Day 1 (Cycle 1), followed by 6 mg/kg, IV (Cycles 2 onward, administered until disease progression); cisplatin 80 mg/m\\^2 IV on Day 1; and EITHER 5-FU 800 mg/m\\^2 continuous IV infusion on Days 1 through 5 OR capecitabine 1000 mg/m\\^2 tablets, PO BID from the evening of Day 1 through the morning of Day 15.","id":"OG001","title":"Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)"}],"paramType":"NUMBER","populationDescription":"FAS","reportingStatus":"POSTED","timeFrame":"BL, Days 1, 22, 43, 64, 85, 106, 127, and every 21 days until disease progression of the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis","title":"Percentage of Participants With a Change in Analgesic Medication During the Study","type":"SECONDARY","unitOfMeasure":"percentage of participants"}